Search Results

There are 47807 results for: content related to: Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson's disease

VIEW

  1. 1 - 20
  2. 21 - 40
  3. 41 - 60
  4. 61 - 80
  5. Next >
  1. You have free access to this content
    Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease

    European Journal of Neurology

    Volume 20, Issue 1, January 2013, Pages: 5–15, J. J. Ferreira, R. Katzenschlager, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, A. Schapira, A. Berardelli and W. H. Oertel

    Article first published online : 22 DEC 2012, DOI: 10.1111/j.1468-1331.2012.03866.x

  2. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease

    Intervention Review

    The Cochrane Library

    Katherine Deane, Sybille Spieker and Carl E Clarke

    Published Online : 21 JAN 2009, DOI: 10.1002/14651858.CD004554.pub2

  3. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complications

    Intervention Review

    The Cochrane Library

    Rebecca Stowe, Natalie Ives, Carl E Clarke, Katherine Deane, van Hilten, Keith Wheatley, Richard Gray, Kelly Handley and Alex Furmston

    Published Online : 7 JUL 2010, DOI: 10.1002/14651858.CD007166.pub2

  4. Catechol-O-methyltransferase inhibitors: Clinical potential in the treatment of Parkinson's disease

    Drug Development Research

    Volume 42, Issue 1, September 1997, Pages: 1–25, Jasper Dingemanse

    Article first published online : 6 DEC 1998, DOI: 10.1002/(SICI)1098-2299(199709)42:1<1::AID-DDR1>3.0.CO;2-I

  5. Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease

    CNS Neuroscience & Therapeutics

    Volume 14, Issue 1, Spring 2008, Pages: 83–93, Andrew J. Lees

    Article first published online : 14 MAR 2008, DOI: 10.1111/j.1527-3458.2007.00035.x

  6. Tolcapone, a Selective Catechol-O-Methyltransferase Inhibitor for Treatment of Parkinson's Disease

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 19, Issue 1, January-February 1999, Pages: 6–20, David R. P. Guay

    Article first published online : 17 JAN 2012, DOI: 10.1592/phco.19.1.6.30516

  7. You have full text access to this OnlineOpen article
    Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase

    British Journal of Clinical Pharmacology

    Volume 48, Issue 4, October 1999, Pages: 513–520, Karin Jorga, Bärbel Fotteler, Peter Heizmann and Rodolfo Gasser

    Article first published online : 24 DEC 2001, DOI: 10.1046/j.1365-2125.1999.00036.x

  8. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations

    Movement Disorders

    Volume 16, Issue 5, September 2001, Pages: 858–866, William Koller, Andrew Lees, Miroslava Doder and Mariese Hely

    Article first published online : 20 SEP 2001, DOI: 10.1002/mds.1175

  9. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease

    Intervention Review

    The Cochrane Library

    Katherine Deane, Sybille Spieker and Carl E Clarke

    Published Online : 21 JAN 2009, DOI: 10.1002/14651858.CD004553.pub2

  10. Early (Uncomplicated) Parkinson's Disease

    European Handbook of Neurological Management

    M. Horstink, E. Tolosa, U. Bonuccelli, G. Deuschl, A. Friedman, P. Kanovsky, J. P. Larsen, A. Lees, W. Oertel, W. Poewe, O. Rascol, C. Sampaio, Pages: 224–244, 2008

    Published Online : 14 JAN 2008, DOI: 10.1002/9780470753279.ch17

  11. You have full text access to this OnlineOpen article
    Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies

    British Journal of Clinical Pharmacology

    Volume 49, Issue 1, January 2000, Pages: 39–48, Karin Jorga, Bärbel Fotteler, Ludger Banken, Paul Snell and Jean-Louis Steimer

    Article first published online : 24 DEC 2001, DOI: 10.1046/j.1365-2125.2000.00113.x

  12. Early (Uncomplicated) Parkinson's Disease

    European Handbook of Neurological Management, Second Edition, Volume 1, Second Edition

    W. H. Oertel, A. Berardelli, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, J. J. Ferreira, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, Pages: 217–236, 2010

    Published Online : 6 SEP 2010, DOI: 10.1002/9781444328394.ch14

  13. Interventions to Achieve Tonic Exposure to Levodopa: Delaying or Preventing the Onset of Motor Complications

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 19, Issue 11P2, November 1999, Pages: 169S–179S, Mark S. Luer

    Article first published online : 17 JAN 2012, DOI: 10.1592/phco.19.17.169S.30886

  14. You have full text access to this OnlineOpen article
    COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet®)

    British Journal of Clinical Pharmacology

    Volume 48, Issue 3, September 1999, Pages: 449–452, Karin M. Jorga and David J. Nicholl

    Article first published online : 24 DEC 2001, DOI: 10.1046/j.1365-2125.1999.00027.x

  15. Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease

    Movement Disorders

    Volume 22, Issue 1, January 2007, Pages: 14–19,

    Article first published online : 6 NOV 2006, DOI: 10.1002/mds.21131

  16. You have full text access to this OnlineOpen article
    Catechol-O-methyltransferase and Its Inhibitors in Parkinson's Disease

    CNS Drug Reviews

    Volume 13, Issue 3, Fall 2007, Pages: 352–379, Maria João Bonifácio, P. Nuno Palma, Luís Almeida and Patrício Soares-da-Silva

    Article first published online : 24 SEP 2007, DOI: 10.1111/j.1527-3458.2007.00020.x

  17. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients

    Movement Disorders

    Volume 13, Issue 4, July 1998, Pages: 643–647, Robert A. Hauser, Eric Molho, Heidi Shale, Simon Pedder and Ernest E. Dorflinger

    Article first published online : 4 NOV 2004, DOI: 10.1002/mds.870130406

  18. You have full text access to this OnlineOpen article
    Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa.

    British Journal of Clinical Pharmacology

    Volume 40, Issue 3, Sep 1995, Pages: 253–262, J. Dingemanse, K. Jorga, G. Zurcher, M. Schmitt, G. Sedek, M. Da Prada and P. Van Brummelen

    Article first published online : 4 JUL 2012, DOI: 10.1111/j.1365-2125.1995.tb05781.x

  19. COMT inhibitors

    Movement Disorders

    Volume 17, Issue S4, July/August 2002, Pages: S45–S51,

    Article first published online : 29 JUL 2002, DOI: 10.1002/mds.5560

  20. Tolcapone added to levodopa in stable parkinsonian patients: A double-blind placebo-controlled study

    Movement Disorders

    Volume 12, Issue 6, November 1997, Pages: 928–934, Dr. Erik Dupont, Jean-Marc Burgunder, Leslie J. Findley, Jan-Edvin Olsson and Ernest Dorflinger

    Article first published online : 4 NOV 2004, DOI: 10.1002/mds.870120615

VIEW

  1. 1 - 20
  2. 21 - 40
  3. 41 - 60
  4. 61 - 80
  5. Next >